Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

Jayashree Kalpathy–Cramer(University of Colorado Denver), Elizabeth R. Gerstner(University of California, Los Angeles), Alona Muzikansky(Johns Hopkins University), J.G. Evans(University of Virginia), Patrick Y. Wen(Dana-Farber Cancer Institute), Dan G. Duda(Harvard University), Stephen Stufflebeam(Athinoula A. Martinos Center for Biomedical Imaging), Vyshak Chandra(Athinoula A. Martinos Center for Biomedical Imaging), Jörg Dietrich(Massachusetts General Hospital), Yangming Ou(Boston Children's Hospital), Tracy T. Batchelor(Brigham and Women's Hospital), Linda Douw(Amsterdam UMC Location Vrije Universiteit Amsterdam), Xiao Da(Athinoula A. Martinos Center for Biomedical Imaging), Bruce R. Rosen(Massachusetts General Hospital), Xuezhu Cai(Boston University), Kyrre E. Emblem(Oslo University Hospital)
Journal of Neuro-Oncology
November 16, 2016
Cited by 82


Related Papers